Abstract: The present invention relates to processes for the preparation of rasagiline mesylate. Also provided is rasagiline mesylate having 90 volume percent of the particles (D90) with sizes less than about 6 ?m and processes for the preparation thereof.

Abstract: Processes for the preparation of palonosetron hydrochloride and its crystalline forms.

Abstract: Pharmaceutical formulations comprising amorphous pemetrexed or its salts, and processes to prepare the formulations.

Abstract: Processes for preparing azacitidine. Further included are processes for the preparation of crystalline azacitidine crystalline Form (I) and mixtures of azacitidine crystalline Forms (I) and (II).

Abstract: Processes for the preparation of amorphous pemetrexed disodium, and removal of residual solvents from amorphous pemetrexed disodium.

Abstract: Pharmaceutical compositions comprising bortezomib for oral or parenteral administration. Specific aspects relate to stable, sugar free pharmaceutical compositions of bortezomib, including its pharmaceutically acceptable salts or solvates, in the form of ready-to-use solutions, lyophilized forms, or physical admixtures, and the preparation thereof. Other aspects include processes for preparing compositions and methods of using compositions for treating various types of cancers in mammals.

Abstract: Pharmaceutical formulations comprising raloxifene or its salts, esters, polymorphs, isomers, hydrates, solvates, or derivatives thereof having defined particle sizes. Also described are processes for preparing formulations and methods of using such formulations.

Abstract: Preparation of ranolazine and intermediates thereof, for use in pharmaceutical compositions comprising ranolazine.

Abstract: Modified release pharmaceutical formulations comprising niacin in a non-swellable core, and processes for preparation of the formulations.

Abstract: The invention provides an efficient method of purification of a modified cytokine. The process includes the use of a chromatographic technique for the purification of the desired cytokine. The purified cytokine can be used as a therapeutic composition.

Abstract: Pharmaceutical formulations comprising a combination of niacin and an oxicam NSAID, for oral administration, and methods of preparing the formulations.

Abstract: Compositions containing atorvastatin, including its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, polymorphs and their mixtures, and processes for preparing the same. Further aspects relate to pharmaceutical formulations comprising compositions containing atorvastatin, or a salt thereof, processes for preparing the same, and their methods of use, treatment and administration.

Abstract: Processes for preparing montelukast acid and its salts.

Abstract: Processes for the preparation of dexlansoprazole, an amorphous form of dexlansoprazole, a solid dispersion of amorphous dexlansoprazole and a pharmaceutically acceptable carrier, and processes for their preparation. Also provided are crystalline compounds 2-[(R)-[(4-chloro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and 2-[(R)-[(4-nitro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, and methods for their preparation.

Abstract: Processes for the preparation of substantially pure lenalidomide. The application also relates to an enriched, substantially pure, and pure amorphous form of lenalidomide and solid dispersions containing amorphous lenalidomide.

Abstract: Solubility-enhanced forms of aprepitant and processes for preparing such forms. The invention also provides solubility-enhanced forms of aprepitant that also possess stability against solid state conversions. Certain solubility-enhanced forms of aprepitant comprise a cyclodextrin or any of its derivatives. Other solubility-enhanced forms of aprepitant comprise fine particle preparations of aprepitant. The invention further provides non-nanoparticulate pharmaceutical formulations prepared using solubility-enhanced forms of aprepitant. The invention also provides taste-masked and orally disintegrating pharmaceutical formulations comprising aprepitant. Further, pharmaceutical formulations comprising solubilityenhanced forms of aprepitant and processes of preparation of such formulations, as well as methods of using them are provided.

Abstract: Intimate mixtures of aprepitant crystalline Form I and crystalline Form II, having specific Hweight ratios of the forms.

Abstract: There is provided salts and polymorphs of sitagliptin, processes for the preparation thereof, and pharmaceutical compositions comprising the same.

Abstract: The present invention is directed to a compounds, methods and compositions for making the compounds and methods of treating a variety of diseases and disease states including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan, comprising the administration of new heterocyclic compounds, particularly substituted pyrimidines.

Abstract: Processes for the preparation of prasugrel and its pharmaceutically acceptable salts thereof. Also disclosed are polymorphic forms of prasugrel hydrochloride and processes for their preparation.